OncoZenge AB is developing BupiZenge™, a lozenge containing bupivacaine that provides targeted local pain relief for patients suffering from oral mucositis, a painful side effect of cancer treatments like chemotherapy and radiotherapy. Clinical studies have shown that BupiZenge™ can reduce mouth pain by 50% compared to standard therapies, offering a non-opioid alternative that improves patients' quality of life.
Funding
Funding not disclosed
Founders
Product
Problem
Patients undergoing cancer treatments like chemotherapy and radiotherapy often suffer from oral mucositis, a painful condition with limited safe and effective treatment options beyond opioids. This unmet need results in compromised nutrition, treatment delays, and increased healthcare costs.
Solution
OncoZenge is developing BupiZenge™, a lozenge containing bupivacaine designed to provide targeted, local pain relief for oral mucositis. BupiZenge™ leverages the well-researched active substance bupivacaine to deliver significant pain relief within minutes, lasting for hours. Clinical trials have demonstrated that BupiZenge™ can halve mouth pain compared to current treatments and is preferred by prescribing physicians, offering a non-opioid alternative that improves patients' ability to eat, drink, and tolerate cancer treatments.
Target Audience
The primary target audience includes patients undergoing chemotherapy or radiotherapy who are experiencing oral mucositis, as well as physicians and oncologists seeking effective non-opioid pain management solutions.
Features
- Lozenge formulation for targeted, local delivery of bupivacaine
- Rapid onset of pain relief within minutes
- Long-lasting pain relief for several hours
- Demonstrated 50% reduction in mouth pain compared to existing treatments in clinical trials
- Potential to reduce or eliminate the need for opioid pain medications
- Potential applications beyond oral mucositis, including mouth and throat surgery, dental applications, and chronic pain conditions